The sentence handed down in a Los Angeles federal courtroom this week closes one chapter in a case that has steadily widened far beyond a single overdose, exposing how loosely regulated access, medical gray areas, and outright illegal distribution converged in the final days of Matthew Perry.
Jasveen Sangha, described by federal prosecutors as a central supplier in a high-volume drug network, was sentenced on April 8, 2026, to 15 years in federal prison after admitting her role in distributing ketamine linked to Perry’s death. The punishment reflects the federal government’s growing willingness to pursue not only end users or intermediaries, but also the suppliers operating behind the scenes of addiction-driven markets.
According to court filings and federal investigators, Sangha operated a drug distribution enterprise out of North Hollywood, supplying ketamine and other controlled substances to a clientele that included individuals seeking access outside traditional medical channels. Authorities determined that ketamine traced back to her operation was among the doses administered to Perry in the days leading up to his death in October 2023.
The case revealed a layered supply chain rather than a single point of failure. Prosecutors outlined a network involving multiple actors, including medical professionals, intermediaries, and individuals within Perry’s personal circle. At least one intermediary obtained ketamine from Sangha and passed it along, while Perry’s assistant was responsible for administering doses. The structure of that network, as presented in court, demonstrated how medical treatment can blur into misuse when oversight breaks down and demand escalates.
Perry, who had publicly discussed his long struggle with substance use and recovery, had been receiving supervised ketamine therapy as part of treatment for depression. However, investigators found that he sought higher or more frequent doses than were being prescribed, turning to illicit sources when legal avenues would not accommodate those requests. That shift from clinical supervision to unregulated supply became a defining factor in the government’s case.
The Los Angeles County Medical Examiner ruled Perry’s death an accidental overdose, identifying ketamine as the primary cause, with contributing factors that included drowning. The findings reinforced a broader concern within both medical and legal communities about the increasing accessibility of ketamine, a substance that has gained legitimacy in controlled therapeutic settings while simultaneously expanding in illicit markets.
Sangha’s sentencing is one of the most significant penalties issued in connection with the case, though she was not the only individual charged. Several others tied to the distribution chain, including physicians and intermediaries, have faced charges or entered plea agreements, underscoring the scope of the investigation. Federal authorities emphasized that the case represents a coordinated effort to address all levels of distribution, from prescription practices to illegal resale.
While Sangha faced a potential sentence far exceeding the term ultimately imposed, the 15-year penalty signals a calibrated but firm response from the court. Prosecutors argued that her operation prioritized profit over safety, pointing to evidence that distribution continued despite known risks associated with the substances being sold. The court’s decision reflects an acknowledgment of both the severity of the outcome and the broader context in which the drugs were supplied.
Beyond the courtroom, the case has intensified scrutiny around ketamine’s dual identity as both a legitimate medical treatment and a drug of misuse. In recent years, the expansion of ketamine-assisted therapy has created new pathways for patients seeking relief from treatment-resistant conditions, but it has also introduced challenges related to regulation, monitoring, and diversion.
For federal authorities, the outcome marks a clear message that accountability will extend across the full chain of distribution when controlled substances contribute to a fatality. For the public, the case underscores a more complicated reality, where legal treatment, personal vulnerability, and illicit access can intersect with fatal consequences.
The legal proceedings connected to the death of Matthew Perry have now resulted in multiple convictions and sentences across those identified in the distribution chain. Federal authorities have indicated that the case remains a reference point in ongoing efforts to investigate and prosecute illegal distribution of controlled substances, particularly in situations where licensed medical treatment and unauthorized supply intersect.